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Aims Severe deficiency of the essential trace element selenium can cause myocardial dysfunction although the mechanism
at cellular level is uncertain. Whether, in clinical practice, moderate selenium deficiency is associated with worse
symptoms and outcome in patients with heart failure is unknown.
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Methods
and results
BIOSTAT-CHF is a multinational, prospective, observational cohort study that enrolled patients with worsening
heart failure. Serum concentrations of selenium were measured by inductively coupled plasma mass spectrometry.
Primary endpoint was a composite of all-cause mortality and hospitalization for heart failure; secondary endpoint was
all-cause mortality. To investigate potential mechanisms by which selenium deficiency might affect prognosis, human
cardiomyocytes were cultured in absence of selenium, and mitochondrial function and oxidative stress were assessed.
Serum selenium concentration (deficiency) was<70 μg/L in 485 (20.4%) patients, who were older, more often women,
had worse New York Heart Association class, more severe signs and symptoms of heart failure and poorer exercise
capacity (6-min walking test) and quality of life (Kansas City Cardiomyopathy Questionnaire). Selenium deficiency was
associated with higher rates of the primary endpoint [hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.06–1.42]
and all-cause mortality (HR 1.52; 95% CI 1.26–1.86). In cultured human cardiomyocytes, selenium deprivation
impaired mitochondrial function and oxidative phosphorylation, and increased intracellular reactive oxygen species
levels.
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Conclusions Selenium deficiency in heart failure patients is independently associated with impaired exercise tolerance and a 50%
higher mortality rate, and impaired mitochondrial function in vitro, in human cardiomyocytes. Clinical trials are needed
to investigate the effect of selenium supplements in patients with heart failure, especially if they have low plasma
concentrations of selenium.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
An aberrant equilibrium of circulating molecules like minerals and
trace elements (for example iron, iodine and zinc) in the patients’
blood is closely involved in the development and progression of
heart failure.1–4 It was shown that up to 50% of patients with heart
failure suffer from some form of malnutrition, like micronutrient
insufficiencies.5,6
Selenium is an essential micronutrient and sufficient concen-
trations are essential for numerous biological functions including
thyroid hormone metabolism, antioxidant defenses, the immune
system and in certain types of cancer.7,8 Severe selenium defi-
ciency in humans is associated with a rare but fatal form of dilated
cardiomyopathy that is restricted to specific geographic regions
(Keshan disease)9 that have a very low amount of selenium in the
soil and therefore in food. Keshan disease is reversible with sele-
nium supplementation.1 Selenium soil content is very variable and
this affects dietary selenium intake. For example, intakes are high
in Venezuela, Canada, the USA, and Japan (>100 μg/day), and much
lower in some parts of Europe (∼40 μg/day).7 Observational stud-
ies in the general population7,10 suggest that selenium deficiency
might be common, however data on serum selenium concentra-
tions in heart failure are scarce.11–13
On a molecular level selenium is incorporated into, and is essen-
tial for the enzymatic activity of 25 different selenoproteins.13 Sele-
nium depletion deprives the cell of its ability to synthesize enzy-
matically active selenoproteins, but the effects on mitochondrial
function, biogenesis and oxidative stress in human cardiomyocytes
are unknown.
Accordingly, we conducted both in vitro experiments on the
effects of selenium deprivation on human cardiomyocytes and
investigated associations between serum concentrations of sele-
nium and the clinical characteristics and outcomes of a large cohort
of patients with heart failure.
Materials and methods
Abbreviated methods are displayed below, for the full materials and
methods section, see online supplementary Methods S1.
BIOSTAT-CHF patient population
We used information and samples from the BIOSTAT-CHF index
cohort, which consists of 2516 patients with heart failure from 69
centres in 11 European countries.14–17 Inclusion criteria included:
age >18 years, symptoms of new-onset or worsening heart failure
and at least one of the following: a left ventricular ejection frac-
tion of ≤ 40%, a plasma B-type natriuretic peptide of >400 pg/mL
or a plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP)
of >2000 pg/mL. Patients could only be included if their treat-
ment did not conform to guideline recommendations [i.e. ≤ 50% of
angiotensin-converting enzyme inhibitors (ACEi)/angiotensin recep-
tor blockers (ARB) and/or beta-blockers] and were anticipated to
have treatment with ACEi/ARBs and/or beta-blockers initiated or
up-titrated. The BIOSTAT-CHF study was approved by the medical
ethics committee for each centre and complies with the Declaration
of Helsinki. All participants provided written informed consent prior
to any study-related procedures. ..
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.. For additional details on the BIOSTAT-CHF study definitions, mea-
surements and outcome analyses and statistical analysis, see online
supplementary Methods S1.
Serum selenium determination
Selenium was measured using a validated inductively coupled plasma
mass spectrometry (ICP-MS) method with a lower limit of quantitation
of 20 μg/L serum. The 78Se isotope concentration was measured
using a Varian 820-MS ICP mass spectrometer. Reference ranges
for serum selenium vary between coutries because of differences in
dietary sources of selenium. For caucasians of European ancestry,
adult reference ranges are between 70 and 130 μg/L.18 Deficiency of
selenium was therefore set at serum levels < 70 μg/L.
For additional details on serum selenium determination, see online
supplementary Methods S1.
Cell culture, cardiomyocyte
differentiation, selenium depletion
and cardiac stress model
Differentiation of HUES9 human pluripotent stem cells (hPSC, Har-
vard Stem Cell Institute) to cardiomyocytes was achieved as described
previously.19–22 For the experiments, cells were grown either in
CDM3 medium supplemented with 100 nM sodium selenite23 (Con-
trol; S5261, Sigma-Aldrich) or in CDM3 medium without added sele-
nium (selenium deficient cells) for 2weeks.
For additional details on the functional characterisation of selenium
depletion of cardiomyocytes (protein extraction and western blot,
RNA extraction and qRT-PCR, immunofluorescence, reactive oxygen
species detection and Seahorse experiments), see online supplemen-
tary Methods S1 and Table S1.
Statistical analyses
Differences between clinical characteristics across quartiles of sele-
nium levels were compared using one-way analysis of covariance
(ANOVA), the Kruskal–Wallis test or the Chi square test where
appropriate. Multivariable logistic regression was used to investi-
gate independent associations with selenium deficiency. The associa-
tion with outcome was investigated using Kaplan–Meier curves and
the log-rank test. For multivariable analyses, Cox regression anal-
ysis was performed on selenium deficiency and standardized sele-
nium levels, correcting for relevant clinical confounders independently
associated with selenium levels (online supplementary Table S2) and
the BIOSTAT-CHF risk models, which were previously published.15
The baseline model included, age, daily protein intake, country,
haemoglobin, C-reactive protein, high-density lipoprotein cholesterol,
albumin, NT-proBNP, sodium and estimated glomerular filtration rate
(eGFR by the Chronic Kidney Disease Epidemiology Collaboration
equation), all independently associated with selenium levels. The
BIOSTAT-CHF risk model for predicting mortality included, age, blood
urea nitrogen, NT-proBNP, haemoglobin and the use of a beta-blocker
at time of inclusion. The BIOSTAT-CHF risk model for predicting
mortality or heart failure hospitalization included age, NT-proBNP,
haemoglobin, the use of a beta-blocker at time of inclusion, a heart fail-
ure hospitalization in the year before inclusion, peripheral oedema, sys-
tolic blood pressure, high-density lipoprotein cholesterol and sodium.
Experimental groups consisted of at least three independent bio-
logical replicates and technical duplicates were used. Data shown are
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Normal
selenium
(≥ 70𝛍g/L)
Selenium-
deficient
(< 70𝛍g/L)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n 1897 485
Demographics
Age (years) 67.8 (12.0) 72.6 (11.3) <0.001
Female sex 456 (24.0%) 158 (32.6%) <0.001
BMI (kg/m2) 28.0 (5.5) 27.5 (5.5) 0.10
Protein intake (g/day) 55.8 (11.5) 52.2 (9.9) <0.001
Ischaemic aetiology (%) 870 (46.7%) 215 (44.9%) 0.47
LVEF (%) 30.5 (9.9) 32.9 (12.7) <0.001
HF subgroup <0.001
HFrEF 1430 (83.6%) 303 (71.8%)
HFmrEF 194 (11.3%) 73 (17.3%)
HFpEF 86 (5.0%) 46 (10.9%)
NYHA class <0.001
I 198 (11.9%) 27 (6.2%)
II 896 (54.0%) 201 (46.4%)
III 512 (30.9%) 179 (41.3%)
IV 52 (3.1%) 26 (6.0%)
Systolic BP (mmHg) 124.5 (21.5) 124.6 (22.7) 0.93
Diastolic BP (mmHg) 75.3 (13.2) 73.4 (12.9) 0.005
Heart rate (bpm) 79.6 (19.5) 80.1 (18.9) 0.63
Smoking 0.074
No 670 (35.4%) 196 (40.5%)
Past 943 (49.8%) 229 (47.3%)
Current 282 (14.9%) 59 (12.2%)
Signs and symptoms
Extent of peripheral oedema <0.001
Not present 706 (44.9%) 100 (24.9%)
Ankle 456 (29.0%) 121 (30.2%)
Below knee 320 (20.4%) 121 (30.2%)
Above knee 90 (5.7%) 59 (14.7%)
Elevated JVP 384 (30.0%) 138 (46.9%) <0.001
Hepatomegaly 252 (13.3%) 81 (16.8%) 0.049
Orthopnoea 605 (32.0%) 215 (44.4%) <0.001
Pulmonary congestion 943 (51.3%) 291 (61.0%) <0.001
Co-morbidities
Anaemia 567 (33.2%) 222 (47.9%) <0.001
Atrial fibrillation 839 (44.2%) 238 (49.1%) 0.056
Diabetes mellitus 599 (31.6%) 170 (35.1%) 0.14
COPD 313 (16.5%) 98 (20.2%) 0.054
CKD 487 (25.7%) 170 (35.1%) <0.001
Hypertension 1178 (62.1%) 310 (63.9%) 0.46
Peripheral arterial
disease
197 (10.4%) 56 (11.5%) 0.46
Stroke 167 (8.8%) 50 (10.3%) 0.30
PCI 429 (22.6%) 98 (20.2%) 0.25
CABG 320 (16.9%) 90 (18.6%) 0.38
Medication
Loop diuretics 1889 (99.6%) 482 (99.4%) 0.57
ACEi/ARB 1391 (73.3%) 333 (68.7%) 0.040
Aldosterone antagonist 1031 (54.3%) 243 (50.1%) 0.094
Beta-blocker 1608 (84.8%) 382 (78.8%) 0.001
Antiplatelets 983 (51.8%) 252 (52.0%) 0.96
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Table 1 Continued
Normal
selenium
(≥ 70𝛍g/L)
Selenium-
deficient
(< 70𝛍g/L)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laboratory
Haemoglobin (g/dL) 13.4 (1.8) 12.4 (1.9) <0.001
Ferritin (μg/L) 107 (52–199) 76 (41–159) <0.001
Transferrin saturation
(%)
17.7
(11.7–25.6)
13.3
(9.0–21.2)
<0.001
Albumin (g/L) 33.1 (8.6) 28.9 (8.6) <0.001
C-reactive protein
(mg/L)
12.1
(5.1–24.2)
17.6
(8.4–32.3)
<0.001
Total cholesterol
(mmol/L)
4.2 (3.4–5.1) 3.8 (3.1–4.6) <0.001
HDL cholesterol
(mmol/L)
1.1 (0.9–1.3) 1.0 (0.8–1.2) 0.001
LDL cholesterol
(mmol/L)
2.6 (1.9–3.2) 2.2 (1.5–3.0) <0.001
HbA1c (%) 6.3 (5.7–7.2) 6.3 (5.8–6.9) 0.96
NT-proBNP (ng/L) 3845
(2242–7681)
5506
(3045–9727)
<0.001
Sodium (mmol/L) 140
(137–142)
139
(136–141)
<0.001
Potassium (mmol/L) 4.2 (3.9–4.6) 4.3 (3.9–4.6) 0.81
Creatinine (μmol/L) 100 (82–126) 106 (83–141) 0.007
eGFR
(mL/min/1.73m2)
61.0
(45.9–80.0)
53.7
(37.7–74.4)
<0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery
bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pul-
monary disease; eGFR, estimated glomerular filtration rate (by Chronic Kidney
Disease-Epidemiology Collaboration equation); HbA1c, glycated haemoglobin;
HDL, high-density lipoprotein; HF, heart failure; HFmrEF, heart failure with
mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; JVP, jugular venous pressure;
LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association;
PCI, percutaneous coronary intervention.
expressed as means ± standard error of the mean (SEM). Differences
were assessed by Student’s t-test. A P-value of < 0.05 was considered
statistically significant.
All tests and analyses were performed using STATA version 15.0
(StataCorp LP, College Station, TX, USA) or GraphPad Prism 7.0
(GraphPad Software, La Jolla, CA, USA).
Results
BIOSTAT-CHF baseline characteristics
Median serum selenium was 87 μg/L [interquartile range (IQR)
73–103] and 485 (20.4%) patients were selenium-deficient
(<70 μg/L). Patients with lower serum selenium concentrations
were older, more often women, had worse symptoms and signs of
heart failure, were more likely to have anaemia, iron deficiency and
chronic kidney disease (eGFR <60mL/min/1.73m2) and had lower
serum albumin and cholesterol (Table 1). In multivariable analyses,
country of residence, higher age, lower protein intake and lower
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Selenium and clinical outcome parameters. Association of selenium levels with (A) 6-min walking test (6MWT) and (B) Kansas
City Cardiomyopathy Questionnaire (KCCQ) results. Kaplan–Meier curves showing the increased risk of chronic heart failure patients with
selenium deficiency (selenium <70 μg/L) for (C) the composite endpoint [all-cause mortality and hospitalization due to heart failure (HF)] and
(D) all-cause mortality. Selenium levels as a continuous variable for hazard ratio (HR) plots using fractional polynomials, showing increasing HR
with decreasing selenium concentrations for both the composite endpoint (E) and all-cause mortality (F). CI, confidence interval.
haemoglobin and albumin concentrations were most strongly
associated with selenium deficiency (baseline model; online
supplementary Table S2). There was considerable geographic
variation in serum selenium concentrations (online supplementary
Figure S1).
Selenium-deficient patients were less likely to complete a 6-min
walking test (6MWT) (54% vs. 67%, P< 0.001) and those that did
had a shorter 6MWT distance [151 (IQR 0–276)m vs. 225 (IQR
0–364)m; P< 0.001]. Selenium-deficient patients also had a lower
overall score on the Kansas City Cardiomyopathy Questionnaire
(KCCQ) [41 (IQR 25–57) vs. 51 (IQR 34–69)] (Figure 1A and
1B). These associations remained after multivariable correction for
baseline associations with serum selenium (coefficient −30, beta
−0.07, P = 0.001 and coefficient −4, beta −0.06, P = 0.001, for
6MWT and KCCQ, respectively). .
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.. Selenium deficiency associates
with higher all-cause mortality
and rehospitalisation for heart failure
Overall, 963 (40%) patients died or were hospitalized for heart
failure during a median follow-up of 21 (IQR 16–27) months. Sele-
nium defiency was strongly associated [hazard ratio (HR) 1.78;
95% confidence interval (CI) 1.54–2.09] with the primary com-
posite endpoint (Figure 1C and Table 2). This association remained
significant (HR 1.21; 95% CI 1.02–1.43) after correction for base-
line variables associated with serum selenium or variables included
in the BIOSTAT-CHF risk model (HR 1.23; 95% CI 1.06–1.42).
Similar associations were found for all-cause mortality (HR 1.52;
95% CI 1.26–1.86) (Figure 1D and Table 2). In sensitivity analy-
ses, we analysed selenium levels as a continuous variable for HR
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Cox regression analyses
HR (95%CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Combined outcome
Univariable 1.78 (1.54–2.09) <0.001
Baseline modela 1.21 (1.02–1.43) 0.028
BIOSTAT-CHF risk modelb 1.23 (1.06–1.42) 0.007
All-cause mortality
Univariable 2.17 (1.83–2.58) <0.001
Baseline modela 1.46 (1.19–1.79) <0.001
BIOSTAT-CHF risk modelc 1.52 (1.26–1.86) <0.001
CI, confidence interval; HR, hazard ratio.
aAge, daily protein intake, country, haemoglobin, C-reactive protein, high-density
lipoprotein cholesterol, albumin, N-terminal pro-B-type natriuretic peptide,
sodium and estimated glomerular filtration rate (by Chronic Kidney Disease-
Epidemiology Collaboration equation).
bAge, N-terminal pro-B-type natriuretic peptide, haemoglobin, use of a beta-
blocker at time of inclusion, heart failure hospitalization in the year before
inclusion, peripheral oedema, systolic blood pressure, high-density lipoprotein
cholesterol and sodium.
cAge, blood urea nitrogen, N-terminal pro-B-type natriuretic peptide,
haemoglobin and use of a beta-blocker at time of inclusion.
plots using fractional polynomials, which showed an increasing
HR with decreasing selenium concentrations for both the com-
posite endpoint (Figure 1E) and all-cause mortality (Figure 1F).
These results were supported by the Kaplan–Meier plots of sele-
nium concentration quartiles, showing gradual increased risk with
lower concentrations (online supplementary Figure S2). Selenium
concentrations were strongly inversely associated with higher rates
of the primary combined outcome (HR 0.87; 95% CI 0.81–0.94)
and mortality alone (HR 0.82; 95% CI 0.76–0.88) in the multi-
variable BIOSTAT-CHF risk model. For patients with serum sele-
nium ≥70 μg/L, higher concentrations were independently associ-
ated with a better outcome (primary endpoint: HR: 0.90; 95% CI
0.82–0.99 and all-cause mortality: HR: 0.79; 95% CI 0.70–0.90).
Low selenium reduces mitochondrial
functionality in human cardiomyocytes
Generated human cardiomyocytes from hPSCs (hPSC-CMs) were
stained for cardiac markers, and cardiac-specific gene expression
was determined for characterization purposes as described before
by Hoes et al.20
hPSC-CMs cultured for 2weeks in selenium-free conditions
showed reduced mitochondrial function (Figure 2A). Selenium
depleted hPSC-CMs showed a basal levels of oxygen consumption
rate of 49% (P< 0.00001) compared to control hPSC-CMs cul-
tured in the presence of selenium (Figure 2A and 2B). Addition of
oligomycin inhibited ATP synthase-linked respiration resulted in
48% less ATP synthase-linked respiration (P< 0.001) (Figure 2B).
Subsequent addition of the uncoupler FCCP induced mitochon-
dria to function at maximum capacity, which showed a 29% lower
maximal capacity (P< 0.005) in selenium-depleted hPSC-CMs
(Figure 2B). Respiration reserve capacity, an estimate of the poten-
tial bioenergetic reserve, was not significantly different between ..
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.. selenium-depleted and control cells (Figure 2B). The same was
true for non-mitochondrial oxygen consumption, proton leak and
coupling efficiency (data not shown).
Mitochondria in selenium-depleted hPSC-CMs also had
decreased expression of OXPHOS proteins [NDUFB8
(FC = 0.56), SDHB (FC = 0.55), UQCRC2 (FC = 0.61) and
ATP5A (FC = 0.61) representing mitochondrial complexes 1 to
3 and 5, respectively] in hPSC-CMs with immunofluorescence
(Figure 2C) and western blot (Figure 2D). To determine mito-
chondrial abundance, hPSC-CMs were checked for TOMM20, a
mitochondrial membrane marker. Based on immunofluorescence
(Figure 2E) and western blot results (Figure 2F) TOMM20 was
reduced in selenium-depleted cardiomyocytes (FC = 0.72;
P = 0.004), albeit to a lesser extent than OXPHOS. Furthermore,
expression of MFN2 (mitochondrial fusion) and FIS1 (mitochon-
drial fission) did not change with selenium deficiency (Figure 2G).
mRNA expression levels of genes involved in (anaerobic) glycoly-
sis or fatty acid metabolism were assessed (Figure 2G) to determine
whether mitochondrial dysfunction was accompanied by a switch in
metabolic substrate. Selenium-depleted hPSC-CMs had decreased
expression of ACACA and ACLY , but expression of ACACB. LDHAwas
upregulated as the result of low selenium, but not GLUT4, PKM,
HK2.
Low selenium promotes stress-induced
increase of reactive oxygen species levels
in human cardiomyocytes
Selenium depletion was associated with more oxidative stress.
Under normal culture conditions, we found a 33% increase of reac-
tive oxygen species (ROS) levels (P< 0.0001) in selenium-depleted
compared to selenium supplemented cardiomyocytes. Induc-
tion of oxidative stress by adding rotenone to hPSC-CMs
resulted in an additional 20% increase of ROS levels only in
selenium-depleted cells (P< 0.005) (Figure 3A). Under oxida-
tive stress conditions, the total increase of ROS levels between
selenium-depleted and control cells was 52% (P< 0.0001).
Addressing the expression of oxidative stress markers at a tran-
scriptional level in selenium-depleted hPSC-CMs showed that,
upon stress induction with rotenone, expression of PGC-1𝛼,
NOS2, AP-1 and RELA are increased two-fold or more (P< 0.05)
(Figure 3B). Subsequently, under selenium replete conditions,
induction of oxidative stress with rotenone, did not result in a
significant induction of the stress markers NOS2, AP-1 and RELA.
Discussion
This analysis shows that many patients with worsening heart
failure have a serum selenium concentration< 70 μg/L and that
this is associated with poorer quality of life, exercise capacity
and prognosis. Serum concentrations of 70–100 μg/L appeared to
have similar adverse associations, suggesting that values <100 μg/L,
found in >50% of this cohort, might be considered abnormal.24,25
In vitro experiments on cultured human cardiac myocytes suggest
that selenium deficiency disrupts mitochondrial electron transport
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Effects of selenium (Se) depletion on mitochondrial respiration and metabolic function. (A) Representative traces for control
cardiomyocytes and Se-deficient cardiomyocytes in a Mito Stress Test. (B) Effects of Se deficiency on basal respiration, maximal respiration,
respiratory reserve and ATP-linked respiration (n = 5). Representative immunofluorescent staining for (C) DAPI, OXPHOS and cardiac troponin
T (cTnT) and (E) DAPI, TOMM20 and 𝛼-actin in control and Se-deficient cardiomyocytes (n = 3). Western blot quantification of (D) NDUFB8,
SDHB, UQCRC2 and ATP5A (mitochondrial complexes 1 to 3 and 5, respectively) (n = 6) and (F) TOMM20 (n = 6). (G) Relative fold-change
of genes involved in (anaerobic) glycolysis or fatty acid metabolism and mitochondrial fusion and fission (n = 6). OCR, oxygen consumption
rate. *P< 0.05; **P< 0.01; ***P< 0.001, ****P< 0.0001.
chain function leading to less efficient production of ATP, increased
production of ROS and intracellular oxidative damage. However,
selenium may not only be a marker of greater disease severity
and worse outcome but also a therapeutic target. We found that
the relationship between selenium deficiency and signs, symptoms
and prognosis were similar or even more pronounced than for
iron deficiency. Clinical trials of intravenous iron supplements
have shown improvements in symptoms and well-being, and trials .
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.. investigating effects on morbidity and mortality are underway.
Unlike iron, selenium is readily absorbed orally. Trials of selenium
supplementation are now required.
Selenium accumulates in biological tissue and is generally
known as an antioxidant due to its presence in selenoproteins
as selenocysteine. Furthermore, it is known to affect produc-
tion of active thyroid hormone T3
26 and anti-inflammatory
and anti-apoptotic capacity.27 With the occurrence of modest
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Effects of selenium (Se) depletion on reactive oxygen species (ROS) levels and transcriptional stress markers. (A) Relative ROS levels
in control and Se-deficient cardiomyocytes, either with or without the addition of rotenone (n = 5). (B) Relative fold-change of genes involved
in cardiomyocyte stress response upon oxidative stress (n = 5). *P< 0.05; **P< 0.01; ***P< 0.001.
deficiency, selenoprotein concentrations and activities are
preferentially lost based on their demand.28 Serum selenium
concentrations are reduced in many other age-related diseases,
including cancer and heart failure.7,28 Appetite and therewith
food intake may be reduced because of dietary advice on salt and
calorie intake, social isolation, possible circulatory congestion and
inflammation-induced malabsorption, although evidence on the
latter is conflicting.12,29 Age-matched healthy controls showed
higher selenium levels than patients with worsening heart failure
(online supplementary Table S3), with only 5% of controls<70 μg/L.
Selenium toxicity can occur with ingestion of excess selenium
and symptoms include nausea, vomiting, nail brittleness and loss,
hair loss, fatigue, irritability and foul breath odour as found in a
study investigating a misformulated liquid dietary supplement that
resulted in 201 cases of selenium poisoning [the median estimated
amount of selenium ingested was 989mg (range: 41–5875mg)].30
Nonetheless, selenium supplementation is considered to be safe
with a recommended dietary allowance of 55 μg/day for persons
≥14 years, with a tolerable upper intake limit of 400 μg/day.30
A meta-analysis of 25 observational studies on selenium sup-
plementation showed a moderate association between increasing
serum selenium concentration and reduced risk of coronary heart
disease.10 However, randomised trials of selenium supplementation
did not show a profound reduction in cardiovascular events or
mortality,10 but these where often performed in small cohorts and
contain several confounding factors (e.g. age and baseline selenium
levels) hampering interpretation and generalization. One major ..
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. confounding factor in these trials is the high mean serum sele-
nium levels, especially in cohorts including subjects from countries
with relatively high intake (USA, Canada).31 Beyond a specific sele-
nium concentration, there may be no further advantage of selenium
supplementation in reducing cardiovascular mortality.32 This is sup-
ported by our data on exercise capacity and quality of life, show-
ing only for selenium concentrations <100 μg/L a negative effect.
Furthermore, selenium is often given in combination with other
vitamins or minerals (e.g. zinc, vitamin C and E and 𝛽-carotene)
making it difficult to identify selenium specific effects.10 A recently
reported trial of older people (aged 70–80 years), many of whom
were not known to have serious cardiac disease, randomly assigned
participants to placebo or supplements of selenium 200 μg/day
and coenzyme Q10 for a median of 5.1 years.33,34 Daily sele-
nium supplements increased serum selenium concentrations from
45–87 μg/L at baseline to 185–245 μg/L at 48months, whereas
it did not change in those assigned to placebo.33 Those receiv-
ing supplements had lower plasma concentrations of NT-proBNP
at 24 and 48months and improved echocardiographic function.34
Furthermore, participants with a serum selenium concentration
<65 μg/L had a higher cardiovascular mortality compared to those
with concentrations >85 μg/L.33 It is unclear whether there is a
synergistic effect of selenium and coenzyme Q10 supplements.
No randomized trial has evaluated the effect of selenium supple-
ments alone in patients with heart failure.
The effects of selenium deprivation was assessed for the first
time in human PSC-derived cardiomyocytes and showed to impair
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
8 N. Bomer et al.
mitochondrial function, biogenesis and oxidative stress. Mitochon-
dria of selenium-deprived cardiomyocytes had a two-fold lower
basal oxygen consumption rate and ATP-linked respiration. Fur-
thermore, on gene expression level, we found decreased expres-
sion ACACA and ACLY , but increased expression of ACACB indicating
decreased de novo lipogenesis and increased inhibition of fatty acid
and glucose oxidation, respectively. LDHA was up-regulated as the
result of low selenium, indicative of anaerobic glycolysis. This was
in concordance with lower levels of oxidative phosphorylation,
implicating a more glycolytic metabolism profile similar to failing
cardiomyocytes.35 We found no evidence for induced mitochon-
drial fission or fusion. One potential mechanism of benefit from
selenium supplementation is the reduction of oxidative stress. ROS
levels were increased in selenium-depleted cardiomyocytes under
normal culture conditions. Upon inhibiting mitochondrial complex
I, ROS levels increased even more with low selenium status, but
not in cardiomyocytes with a sufficient selenium status, implying
non-optimal working antioxidant machinery. In the acute phase fol-
lowing myocardial infarction and especially subsequent reperfusion,
oxidative damage is predominant. One major source for myocar-
dial ROS lies within the mitochondria and its production is linked
to glutathione.33,36,37 Glutathione is a selenium-containing enzyme
and an important antioxidant in human. Among the 25 selenopro-
teins in mammals, the family of glutathione peroxidases is a major
group whose function is well understood.1 Nevertheless, much is
still unknown of the effect of the other selenoproteins and more
research regarding the fundamental mechanisms of these proteins
on cardiac homeostasis is necessary.
Limitations
In this retrospective study we only investigated the associations
of selenium serum levels with clinical characteristics and out-
comes. No data were currently available on other proteomic
markers of selenium-dependent pathways, nor oxidative stress.
As a result, other signalling components such as selenoprotein P
or gluthatione peroxidase were not investigated next to serum
selenium. Furthermore, reference ranges for serum selenium vary
between coutries because of differences in dietary sources of
selenium. For Caucasians of European ancestry, adult reference
ranges are between 70 and 130 μg/L. Deficiency of selenium was
therefore set at serum levels <70 μg/L. Finally, although numerous
associations were identified between selenium and clinical mea-
surements/outcomes, more research regarding the fundamental
mechanisms of selenium on cardiac homeostasis and the potential
benefits of selenium supplements in patients with heart failure and
low serum selenium concentrations is necessary.
Conclusions
In conclusion, selenium is required to maintain health including
normal mitochondrial and cardiac function. Many older people,
with and without heart failure, have low serum concentrations
of selenium, suggesting deficiency. In patients with heart failure,
low serum concentrations are associated with more severe symp-
toms and signs and a worse prognosis. Selenium supplements safely ..
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.. correct low serum concentrations and in a trial of older people,
many of whom did not have serious cardiovascular disease, a com-
bination of selenium and coenzyme Q10 supplements improved
outcome. Selenium is readily available, inexpensive and has been
thoroughly tested for toxicity, making it a potentially important
‘nutraceutical’. Having said this, we would like to state that by
using an observational study we are unable to attribute cause and
effect of selenium deficiency. Although we show significant effects
on mitochondrial function and ROS of in vitro cultured cardiomy-
ocytes, these functional data are suggestive and do not constitute
such proof. Therefore, therapeutic trials are needed to achieve
conclusive evidence of a causative role of selenium deficiency in
heart failure patients and to determine the benefits of selenium
supplements in patients with heart failure and low serum selenium
concentrations.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Methods S1. Supplementary methods.
Table S1. Primer sequences as used for RT-qPCR expression
analyses.
Table S2. Multivariable logistic regression analysis between the
prevalence of selenium deficiency (< 70 μg/L) and baseline charac-
teristics.
Table S3. Baseline characteristics of healthy controls against
BIOSTAT-CHF patients.
Figure S1. Geographic variation in serum selenium concentra-
tions.
Figure S2. Kaplan–Meier plots by quartile of selenium concentra-
tion for the primary endpoint of all-cause mortality or heart failure
hospitalization and the secondary endpoint of all-cause mortality.
Acknowledgements
The authors thank Silke Oberdorf-Maass for her excellent technical
assistance.
Funding
BIOSTAT-CHF was funded by a grant from the European Com-
mission (FP7-242209-BIOSTAT-CHF). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Conflict of interest: none declared.
References
1. Loscalzo J. Keshan disease, selenium deficiency, and the selenoproteome. N Engl
J Med 2014;370:1756–1760.
2. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, BanasiakW, Lok DJ,
Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska
EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am
Heart J 2013;165:575–582.e3.
3. Yoshihisa A, Abe S, Kiko T, Kimishima Y, Sato Y, Watanabe S, Kanno Y,
Miyata-Tatsumi M, Misaka T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T,
Kunii H, Nakazato K, Ishida T, Takeishi Y. Association of serum zinc level with
prognosis in patients with heart failure. J Card Fail 2018;24:375–383.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Selenium deficiency and heart failure 9
4. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793–803.
5. Hughes CM, Woodside JV, McGartland C, Roberts MJ, Nicholls DP, McKeown
PP. Nutritional intake and oxidative stress in chronic heart failure. Nutr Metab
Cardiovasc Dis 2012;22:376–382.
6. McKeag NA, McKinley MC, Harbinson MT, McGinty A, Neville CE, Woodside
JV, McKeown PP. Dietary micronutrient intake and micronutrient status in
patients with chronic stable heart failure: an observational study. J Cardiovasc Nurs
2017;32:148–155.
7. Rayman MP. Selenium and human health. Lancet 2012;379:1256–1268.
8. Benstoem C, Goetzenich A, Kraemer S, Borosch S, Manzanares W, Hardy G,
Stoppe C. Selenium and its supplementation in cardiovascular disease – what do
we know? Nutrients 2015;7:3094–3118.
9. Yang GQ, Ge KY, Chen JS, Chen XS. Selenium-related endemic diseases and the
daily selenium requirement of humans. World Rev Nutr Diet 1988;55:98–152.
10. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and
coronary heart disease: a meta-analysis. Am J Clin Nutr 2006;84:762–773.
11. de Lorgeril M, Salen P, Accominotti M, Cadau M, Steghens JP, Boucher F, de
Leiris J. Dietary and blood antioxidants in patients with chronic heart failure.
Insights into the potential importance of selenium in heart failure. Eur J Heart Fail
2001;3:661–669.
12. Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, Clark
AL, Cleland JG. The effect of micronutrient supplementation on quality-of-life and
left ventricular function in elderly patients with chronic heart failure. Eur Heart J
2005;26:2238–2244.
13. Alexanian I, Parissis J, Farmakis D, Pantziou C, Ikonomidis I, Paraskevaidis I,
Ioannidou S, Sideris A, Kremastinos D, Lekakis J, Filippatos G. Selenium con-
tributes to myocardial injury and cardiac remodeling in heart failure. Int J Cardiol
2014;176:272–273.
14. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P,
Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van
Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M. A systems BIOlogy study
to TAilored treatment in chronic heart failure: rationale, design, and baseline
characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016;18:716–726.
15. Voors AA, OuwerkerkW, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P,
Ng LL, Metra M, Ter Maaten JM, Lang CC, Hillege HL, van der Harst P,
Filippatos G, Dickstein K, Cleland JG, Anker SD, Zwinderman AH. Development
and validation of multivariable models to predict mortality and hospitalization in
patients with heart failure. Eur J Heart Fail 2017;19:627–634.
16. Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CS, Anker
SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten
JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman
AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA. Comparing
biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm
and reduced vs. preserved ejection fraction. Eur Heart J 2018;39:3867–3875.
17. Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ,
Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van
der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der
Meer P, Voors AA. Identifying pathophysiological mechanisms in heart failure with
reduced versus preserved ejection fraction. J Am Coll Cardiol 2018;72:1081–1090.
18. Moffat A C, OsseltonMD,Widdop B,Watts J. Clarke’s Analysis of Drugs and Poisons,
4th ed. London: Pharmaceutical Press; 2011.
19. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S,
Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD,Wu JC. Chemically
defined generation of human cardiomyocytes. Nat Methods 2014;11:855–860.
20. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BN,
Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P. Iron deficiency
impairs contractility of human cardiomyocytes through decreased mitochondrial
function. Eur J Heart Fail 2018;20:910–919. .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. 21. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, Hsiao C, Kamp TJ,
Palecek SP. Directed cardiomyocyte differentiation from human pluripotent stem
cells by modulating Wnt/𝛽-catenin signaling under fully defined conditions. Nat
Protoc 2013;8:162–175.
22. Ovchinnikova E, Hoes M, Ustyantsev K, Bomer N, de Jong TV, van der Mei H,
Berezikov E, van der Meer P. Modeling human cardiac hypertrophy in stem
cell-derived cardiomyocytes. Stem Cell Reports 2018;10:794–807.
23. Zhang C, Deng Y, Lei Y, Zhao J, Wei W, Li Y. Effects of selenium on myocardial
apoptosis by modifying the activity of mitochondrial STAT3 and regulating
potassium channel expression. Exp Ther Med 2017;14:2201–2205.
24. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P,
McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS; Cardio-
vascular Outcomes Research Consortium. Monitoring clinical changes in
patients with heart failure: a comparison of methods. Am Heart J 2005;150:
707–715.
25. Spertus JA, Jones PG. Development and validation of a short version of
the Kansas City cardiomyopathy questionnaire. Circ Cardiovasc Qual Outcomes
2015;8:469–476.
26. Schomburg L, Köhrle J. On the importance of selenium and iodine metabolism
for thyroid hormone biosynthesis and human health. Mol Nutr Food Res
2008;52:1235–1246.
27. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM,
Cai G, Mahaney MC, Comuzzie AG, Dyer TD, Walder KR, Zimmet P, MacCluer
JW, Collier GR, Kissebah AH, Blangero J. Genetic variation in selenoprotein S
influences inflammatory response. Nat Genet 2005;37:1234–1241.
28. McCann JC, Ames BN. Adaptive dysfunction of selenoproteins from the perspec-
tive of the triage theory: why modest selenium deficiency may increase risk of
diseases of aging. FASEB J 2011;25:1793–1814.
29. Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am
Coll Cardiol 2001;37:1765–1774.
30. MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R, Wolkin A, Mar-
tin C, Burk RF, Dunn JR, Green AL, Hammond R, Schaffner W, Jones TF.
Acute selenium toxicity associated with a dietary supplement. Arch Intern Med
2010;170:256–261.
31. Bleys J. Serum selenium levels and all-cause, cancer, and cardiovascular mortality
among US adults. Arch Intern Med 2008;168:404.
32. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, Fari-
naro E, Clark LC, Reid ME. Effects of selenium supplementation on cardiovascular
disease incidence and mortality: secondary analyses in a randomized clinical trial.
Am J Epidemiol 2006;163:694–699.
33. Alehagen U, Alexander J, Aaseth J. Supplementation with selenium and coen-
zyme Q10 reduces cardiovascular mortality in elderly with low selenium sta-
tus. A secondary analysis of a randomised clinical trial. PLoS One 2016;11:
e0157541.
34. Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovas-
cular mortality and N-terminal-proBNP reduced after combined selenium and
coenzyme Q10 supplementation: a 5-year prospective randomized double-blind
placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 2013;167:
1860–1866.
35. Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol
2018;15:457–470.
36. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M,
Cambien F, Meyer J, Lackner KJ; AtheroGene Investigators. Glutathione peroxi-
dase 1 activity and cardiovascular events in patients with coronary artery disease.
N Engl J Med 2003;349:1605–1613.
37. van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative
stress in heart failure: past, present and future. Eur J Heart Fail 2019;21:
425–435.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
